Media coverage about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) has been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Cipher Pharmaceuticals earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.1743148898817 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Cipher Pharmaceuticals (NASDAQ CPHR) remained flat at $2.99 during trading on Tuesday. Cipher Pharmaceuticals has a 12-month low of $2.55 and a 12-month high of $4.81. The firm has a 50 day moving average of $3.05 and a 200 day moving average of $3.00.

WARNING: This report was first posted by Watch List News and is owned by of Watch List News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cipher-pharmaceuticals-cphr-share-price/1530193.html.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

Insider Buying and Selling by Quarter for Cipher Pharmaceuticals (NASDAQ:CPHR)

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.